Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EPI
Inchon, South Korea
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Epibiotech is advancing a pipeline of cell, antibody, and small molecule therapies primarily for alopecia and alopecia areata. Lead assets are in Phase 1/2 clinical trials. Notable results include early clinical and preclinical evidence of hair growth promotion with ASC and DKK1 knock-out ASC therapy in alopecia models. Their antibody and small molecule programs for RIPK1 are in preclinical or early clinical development with a strong scientific rationale for inhibition of hair loss pathways.
- Therapeutic areas
- Dermatology
- Modalities
- Cell therapyMonoclonal antibodySmall moleculeChemical drugs
- Industry
- Biotech
02
Partnerships
Shanghai Institute of Organic ChemistryGSK
Beyond the preview
Go deeper on EPI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPI.